ASX Sector Insights | Actionable Market Analysis

Insights

Videos

Pricing

About us

Contact us

Stakk (ASX: SKK): Surges on Growth Momentum After Record Revenue Expansion

Jun 3, 2026

Proactive Equities Team

Stakk (ASX: SKK) has surged, reporting record $5.52 million in March quarter revenue and 186% growth, driven by its Stakk IQ embedded finance platform. Expanding across Australian and U.S. banks, healthcare, and regulated industries, it secured major contracts, lifting ARR toward A$26 million.

Has Tivan (ASX: TVN) Formed a Sustainable Long-Term Floor?

Jun 3, 2026

Proactive Equities Team

Tivan (ASX: TVN) develops critical minerals across Australia and Timor-Leste, led by the Speewah Fluorite project. Following a post-feasibility sell-off and rising cash burn, the stock faces a neutral-to-bearish technical outlook ahead of its late-2026 Final Investment Decision.

Is Tamboran Resources Corporation (ASX: TBN) Uptrend Still Intact Following Its Pullback to Support?

Jun 1, 2026

Proactive Equities Team

Tamboran Resources is a pre-production shale gas developer in the Beetaloo Basin, advancing toward first gas in 2026. Strong drilling results, contracts, and infrastructure progress support its uptrend, though risks remain around execution, funding, and market access beyond initial supply agreements.

Can Australian Mines (ASX: AUZ) Hold Its Breakout and Target Higher Levels?

Jun 1, 2026

Proactive Equities Team

Australian Mines (ASX: AUZ) is a critical minerals explorer focused on battery metals, rare earths, and gold across Australia and Brazil, advancing projects like Sconi and Flemington while leveraging strong commodity trends and strategic funding to drive its 2026 share price recovery.

Telix Pharmaceuticals (ASX: TLX) Rebounds From Heavy Sell-Off Reignites Investor Optimism

Jun 1, 2026

Proactive Equities Team

Telix Pharmaceuticals (ASX: TLX) is recovering after a sharp biotech sell-off driven by regulatory and legal concerns. Renewed investor confidence follows strong revenue growth, progress in Phase 3, and a Regeneron partnership, with FY2026 revenue nearing US$1 billion and pipeline milestones advancing.

Is Neuren Pharmaceuticals (ASX: NEU) Poised to Reclaim Higher Levels After Forming a Higher Low?

May 28, 2026

Proactive Equities Team

Neuren Pharmaceuticals (ASX: NEU) is a rare-disease biotech generating revenue from DAYBUE while advancing NNZ-2591. After declines from regulatory and guidance setbacks, improving US rollout and technical strength suggest a recovery, with the stock forming higher lows and testing key resistance levels.

1...49 50 51...73

Page 50 of 73

1...49 50 51...73

Page 50 of 73